AstraZeneca announced it will sell the full commercialization and development rights of its late-stage small molecule antibiotics business to Pfizer, while AstraZeneca focuses on developing therapies for other main areas, according to a press release.
{iframe}http://www.healio.com/infectious-disease/antimicrobials/news/online/%7B9a715254-650c-4b70-8015-07f0f2556a7e%7D/astrazeneca-enters-agreement-with-pfizer-over-antibiotics-portfolio{/iframe}